文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

固定低剂量纳武单抗与苯达莫司汀联合治疗高危复发/难治性经典型霍奇金淋巴瘤儿童患者

Combination of fixed low-dose nivolumab and bendamustine in children with high-risk relapsed/refractory classical Hodgkin lymphoma.

作者信息

Srinivasan Shyam, Narayan Aditya, Dhamne Chetan, Chichra Akanksha, Khemani Poonam, Dhariwal Nidhi, Ranjan Raghwesh, Shah Sneha, Shet Tanuja, Gollamudi Venkata Rama Mohan, Roy Moulik Nirmalya, Banavali Shripad D, Narula Gaurav

机构信息

Department of Paediatric Oncology, Tata Memorial Hospital/ACTREC, Mumbai, India.

Homi Bhabha National Institute, Mumbai, India.

出版信息

Br J Haematol. 2025 May 20;207(1):249-53. doi: 10.1111/bjh.20148.

DOI:10.1111/bjh.20148
PMID:40394816
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12234263/
Abstract

A retrospective study of 18 pediatric patients with high-risk relapsed/refractory classical Hodgkin lymphoma demonstrated that a fixed low-dose combination of nivolumab and bendamustine achieved an 88% complete response rate, with 1-year progression-free survival (PFS) of 88.2% and overall survival (OS) of 94.4%.

摘要

一项针对18例高危复发/难治性经典型霍奇金淋巴瘤儿科患者的回顾性研究表明，纳武单抗与苯达莫司汀的固定低剂量联合方案实现了88%的完全缓解率，1年无进展生存率（PFS）为88.2%，总生存率（OS）为94.4%。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22c4/12234263/66df926a1d61/BJH-207-249-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22c4/12234263/66df926a1d61/BJH-207-249-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22c4/12234263/66df926a1d61/BJH-207-249-g002.jpg

相似文献

[1]
Combination of fixed low-dose nivolumab and bendamustine in children with high-risk relapsed/refractory classical Hodgkin lymphoma.

Br J Haematol. 2025-5-20

[2]
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).

Cochrane Database Syst Rev. 2018-7-12

[3]
Clinical features and outcomes of newly diagnosed classical Hodgkin lymphoma patients in Saudi Arabia: a multicenter cohort study.

Sci Rep. 2025-5-26

[4]
Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials.

Ann Oncol. 2025-4

[5]
A Multicenter Real-World Study of Outcomes in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with a Polatuzumab Vedotin-Based Regimen in a Compassionate Use Program in Malaysia.

Asia Pac J Clin Oncol. 2025-6-27

[6]
Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.

Cochrane Database Syst Rev. 2017-4-27

[7]
High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.

Cochrane Database Syst Rev. 2012-1-18

[8]
Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trial.

Haematologica. 2025-7-3

[9]
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.

Cochrane Database Syst Rev. 2012-9-12

[10]
Nivolumab plus relatlimab in patients with relapsed or progressed B-cell malignancies in RELATIVITY-022.

Blood Adv. 2025-3-3

本文引用的文献

[1]
Immune checkpoint inhibitor combinations-current and emerging strategies.

Br J Cancer. 2023-4

[2]
Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults.

Blood. 2023-4-27

[3]
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.

J Clin Oncol. 2023-1-10

[4]
A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma.

Hemasphere. 2020-9-23

[5]
A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure.

Hemasphere. 2020-6-8

[6]
Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi.

Bone Marrow Transplant. 2020-12

[7]
Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group.

Hemasphere. 2020-1-10

[8]
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.

Blood. 2019-4-5

[9]
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.

Ann Oncol. 2019-2-1

[10]
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

J Clin Oncol. 2018-3-27

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索